BRAF and colorectal carcinoma: Anti-VEGF and anti-EGFR monoclonal antibodies are currently recognized as targeted therapeutic options for advanced CRC [7], but the anti-EGFR monoclonal antibodies panitumumab and cetuximab have significant effects on patients with wild-type RAS and BRAF, while they have poor effects on patients with mutant RAS and BRAF.